NO20054957L - Subtituerte karboksylsyrer - Google Patents

Subtituerte karboksylsyrer

Info

Publication number
NO20054957L
NO20054957L NO20054957A NO20054957A NO20054957L NO 20054957 L NO20054957 L NO 20054957L NO 20054957 A NO20054957 A NO 20054957A NO 20054957 A NO20054957 A NO 20054957A NO 20054957 L NO20054957 L NO 20054957L
Authority
NO
Norway
Prior art keywords
compositions
useful
carboxylic acids
substituted carboxylic
ptp
Prior art date
Application number
NO20054957A
Other languages
English (en)
Other versions
NO20054957D0 (no
Inventor
Michael C Van Zandt
Kerry Jeanne Combs
Shaojing Hu
Darren Whitehouse
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of NO20054957D0 publication Critical patent/NO20054957D0/no
Publication of NO20054957L publication Critical patent/NO20054957L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Den foreliggende oppfinnelse er relatert til blandinger og farmasøytisk akseptable salter av formel (I): som er nyttige i behandling av metabolske forstyrrelser relatert til insulinmotstand eUer hyperglycemi. Disse blandingene inkluderer inhibitorer av protein tyrosin fosfatase (PTP-IB) som er nyttige i behandling av diabetes og andre PTP-IB- medierte sykdommer, som kreft, nevrodegenrative sykdommer og lignende. Blandingene av oppfinnelsen er også nyttige i farmasøytiske komposisjoner og metoder for behandling av de nevnte tilstandene.
NO20054957A 2003-04-30 2005-10-25 Subtituerte karboksylsyrer NO20054957L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46705703P 2003-04-30 2003-04-30
PCT/US2004/011371 WO2004099168A2 (en) 2003-04-30 2004-04-14 Substituted carboxylic acids

Publications (2)

Publication Number Publication Date
NO20054957D0 NO20054957D0 (no) 2005-10-25
NO20054957L true NO20054957L (no) 2006-01-23

Family

ID=33435014

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054957A NO20054957L (no) 2003-04-30 2005-10-25 Subtituerte karboksylsyrer

Country Status (13)

Country Link
US (2) US7358364B2 (no)
EP (1) EP1620420A2 (no)
JP (1) JP2006525329A (no)
KR (1) KR20060006953A (no)
CN (1) CN1812977A (no)
AU (1) AU2004236173B2 (no)
BR (1) BRPI0409914A (no)
CA (1) CA2523714A1 (no)
EA (1) EA200501710A1 (no)
MX (1) MXPA05011524A (no)
NO (1) NO20054957L (no)
WO (1) WO2004099168A2 (no)
ZA (1) ZA200509631B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1812977A (zh) 2003-04-30 2006-08-02 药物研发有限责任公司 取代羧酸
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
FR2869615B1 (fr) * 2004-05-03 2007-11-16 Merck Sante Soc Par Actions Si Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
CA2585550A1 (en) * 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids
EP1844043A2 (en) * 2004-11-18 2007-10-17 The Institutes for Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids for the treatment of diabetes
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
BRPI0709033A2 (pt) 2006-03-29 2011-06-21 Velacor Therapeutics Pty Ltd composição farmacêutica, métodos de tratamento ou prevenção de doença neurodegenerativa numa pessoa, de inibição ou redução da fosforilação de uma proteìna tau num neurÈnio, célula glial ou corpo de lewy, de intensificação da atividade de pp2a e de inibição da atividade de gsk3 num neurÈnio ou célula glial e uso de selenato ou sal farmaceuticamamente aceitável do mesmo
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8507534B2 (en) 2007-12-07 2013-08-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN101910134B (zh) 2007-12-07 2014-03-19 沃泰克斯药物股份有限公司 环烷基甲酰氨基-吡啶苯甲酸类的生产方法
CN103382201B (zh) 2008-02-28 2016-12-28 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
US9302996B2 (en) 2010-12-17 2016-04-05 Mitsubishi Tanabe Pharma Corporation Continuous arycyclic compound
JP5977349B2 (ja) 2012-06-15 2016-08-24 田辺三菱製薬株式会社 芳香族複素環化合物
WO2015006520A1 (en) * 2013-07-11 2015-01-15 Bristol-Myers Squibb Company Ido inhibitors
WO2015073231A1 (en) 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
SI3221692T1 (sl) 2014-11-18 2021-11-30 Vertex Pharmaceuticals Inc. Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo
US10669473B2 (en) * 2015-01-20 2020-06-02 Cynora Gmbh Organic molecules for use in optoelectronic components

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1176339A (en) * 1965-12-27 1970-01-01 Lilly Co Eli Hydrocinnamic Acid Compounds and Processes for making them
IL30498A0 (en) 1967-08-14 1968-10-24 Merck & Co Inc Process for the preparation of phenyl salicylic acid compounds and intermediates used therein
CH542806A (de) * 1967-10-06 1973-10-15 Ciba Geigy Ag Verfahren zur Herstellung einer neuen Aryloxyalkansäure und ihrer Salze
CH499526A (de) * 1968-06-06 1970-11-30 Ciba Geigy Ag Verfahren zur Herstellung von neuen Tetrazolderivaten
US3755603A (en) * 1970-07-01 1973-08-28 Syntex Corp Biphenylyloxyacetic acids in pharmaceutical compositions
DE2205732A1 (de) 1972-02-08 1973-08-16 Thomae Gmbh Dr K Neue 4-(4-biphenylyl)-butensaeurederivate
NL7301246A (no) * 1972-02-14 1973-08-16
DE2358789A1 (de) * 1973-02-07 1975-06-05 Merck Patent Gmbh Hydratropasaeure-derivate und verfahren zu ihrer herstellung
FR2457275A1 (fr) 1979-05-21 1980-12-19 Fabre Sa Pierre Acides p-biphenyl-4 methyl-2 buten-3 oiques utiles dans le traitement des rhumatismes
TW268952B (no) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5886022A (en) 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
AU715764B2 (en) 1996-01-23 2000-02-10 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
ES2311571T3 (es) 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
JP2000509373A (ja) * 1996-04-19 2000-07-25 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
WO1999011255A1 (fr) 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes
CO5011105A1 (es) 1997-12-22 2001-02-28 Novartis Ag Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion
AU2713699A (en) * 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
EE200000573A (et) 1998-03-31 2002-04-15 The Institutes For Pharmaceutical Discovery, Llc Asendatud indoolalkaanhapped
ATE228120T1 (de) 1998-05-12 2002-12-15 Wyeth Corp Biphenylsulfonylarylcarbonsäuren verwendbar zur behandlung von insulin resistenz und hyperglycemia
CA2330558A1 (en) 1998-05-12 1999-11-18 Wyeth (2-acylaminothiazole-4-yl)acetic acid derivatives
US6232322B1 (en) * 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6221902B1 (en) * 1998-05-12 2001-04-24 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
JP2002514635A (ja) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン耐性および高血糖の処置に有用なビフェニルオキソ−酢酸
AU4072799A (en) * 1998-05-12 1999-12-13 American Home Products Corporation 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
EE200100556A (et) 1999-04-28 2003-02-17 Aventis Pharma Deutschland Gmbh Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
EE200100708A (et) 1999-06-25 2003-02-17 The Institutes For Pharmaceutical Discovery, Llc Asendatud fenoksüäädikhapped
AU4398801A (en) 2000-03-22 2001-10-03 Banyu Pharmaceutical Co., Ltd. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
WO2001083464A1 (fr) 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire
EP1288199A4 (en) 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
WO2001083461A1 (fr) 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Derives de thiazole et d'oxazole
EP1301516B1 (en) 2000-07-07 2006-03-22 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
JPWO2002028844A1 (ja) 2000-09-29 2004-02-12 塩野義製薬株式会社 チアゾールおよびオキサゾール誘導体
JP2004521124A (ja) 2001-02-09 2004-07-15 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類
MXPA03011558A (es) 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
DE10150172A1 (de) 2001-10-11 2003-04-30 Morphochem Ag Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren
JP4219810B2 (ja) 2001-10-26 2009-02-04 塩野義製薬株式会社 Ｍｍｐ阻害作用を有するスルホンアミド誘導体
CA2469228A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7297715B2 (en) 2002-07-30 2007-11-20 Merck & Co., Inc. PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
WO2004020409A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
US20040248937A1 (en) 2003-04-14 2004-12-09 The Institute For Pharmaceutical Discovery Llc Substituted phenylalkanoic acids for the treatment of diabetes
CN1812977A (zh) 2003-04-30 2006-08-02 药物研发有限责任公司 取代羧酸
US7538241B2 (en) 2003-12-26 2009-05-26 Kyowa Hakko Kogyo Co., Ltd. Hsp90 family protein inhibitors
US20060100251A1 (en) 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery, Llc Substituted phenylalkanoic acids

Also Published As

Publication number Publication date
KR20060006953A (ko) 2006-01-20
US20090082392A1 (en) 2009-03-26
WO2004099168A3 (en) 2005-02-24
AU2004236173B2 (en) 2008-07-03
BRPI0409914A (pt) 2006-04-25
EP1620420A2 (en) 2006-02-01
NO20054957D0 (no) 2005-10-25
JP2006525329A (ja) 2006-11-09
ZA200509631B (en) 2007-02-28
WO2004099168A2 (en) 2004-11-18
US7358364B2 (en) 2008-04-15
AU2004236173A1 (en) 2004-11-18
EA200501710A1 (ru) 2006-06-30
MXPA05011524A (es) 2006-03-21
CA2523714A1 (en) 2004-11-18
US20040266788A1 (en) 2004-12-30
CN1812977A (zh) 2006-08-02

Similar Documents

Publication Publication Date Title
NO20054957L (no) Subtituerte karboksylsyrer
NO20054769L (no) Substituerte fenylalkansyrer
NO20054958L (no) Substitulerte aminokarboksylsyrer
NO20055129L (no) Fenylsubstituerte karboksylsyrer
TW200630327A (en) Substituted phenylalkanoic acids
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
WO2004071447A3 (en) Substituted azole derivatives as therapeutic agents
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
WO2006055708A3 (en) Heterocycle substituted carboxylic acids for the treatment of diabetes
WO2004071448A3 (en) Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
TW200630354A (en) Substituted amino carboxylic acids
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
WO2008033932A3 (en) Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
TW200631949A (en) Substituted carboxylic acids

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application